Heart Disease News and Research

Latest Heart Disease News and Research

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.

23 Apr 2010

SVS publishes first supplement on diversity articles to Journal of Vascular Surgery

The Society for Vascular Surgery published its first supplement on diversity articles to its Journal of Vascular Surgery in April 2010.

23 Apr 2010

Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted it patent number GB2460597 titled "N,N-Disubstituted aminoalkylBiPhenyl Antagonists OF Prostaglandin d2 RECEPTORS."

23 Apr 2010

Tryton Medical widens European availability of Side Branch Stent System

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the launch of the TRYTON Side Branch Stent™ System in Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. The stent is used to treat bifurcation lesions, the largest unmet need confronting interventional cardiology.

23 Apr 2010

Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress

Boston-based medical technology firm Gelesis, Inc. unveiled its capsulated device Attiva™, and presented data showing that Attiva™ significantly increased the post-meal feeling of satiety and reduced hunger between meals in obese patients. This data was presented today at the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting & Clinical Congress.

23 Apr 2010

Genetic tests that may replace biopsies

Genetic tests conducted on blood samples may replace the current biopsies when it comes to checking if immune systems are rejecting new organs of heart transplant patients. The test would be far less invasive and uncomfortable as compared to the biopsies, not to mention more affordable.

23 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Boston Scientific introduces new Kinetix Guidewire for use in PCI procedures

Boston Scientific Corporation today announced the launch of its new Kinetix™ Guidewire for use in percutaneous coronary intervention (PCI) procedures. Guidewires are small flexible wires physicians use to deliver interventional devices such as drug-eluting stents. The Kinetix Guidewire features a unique micro-cut nitinol sleeve designed for significantly improved torque control compared to conventional spring coil guidewires.

23 Apr 2010

Acacia Research reports record first-quarter license fee revenues of $39.77M

Acacia Research Corporation today reported results for the three months ended March 31, 2010.

23 Apr 2010

AB SCIEX to collaborate in disease studies with Samuel Lunenfeld Research Institute of Mount Sinai Hospital

AB SCIEX, a global leader in life science analytical technologies, today announced that it is collaborating with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, one of the world's leading centers for biomedical research, to improve disease studies. The project is focused on better understanding cancer, diabetes and heart disease by advancing the study of proteins through the use of an emerging mass spectrometry platform currently under development by AB SCIEX.

22 Apr 2010

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Baxter International Inc. today reported first quarter net income of $525 million, an increase of 2 percent from $516 million reported in the first quarter of 2009. Earnings per diluted share of $0.86 increased 4 percent from $0.83 per diluted share reported in the prior-year period. Baxter's first quarter financial results included a one-time, non-cash special charge of $39 million (or $0.07 per diluted share) related to a change in the tax treatment of post-retirement prescription drug benefits under recent U.S. healthcare reform legislation.

From Baxter International Inc. 22 Apr 2010

New campaign highlights dangers of carrying excess weight around waist

Cancer Research UK has joined forces with the British Heart Foundation and Diabetes UK to launch a new campaign to raise awareness of the dangers of carrying excess weight around the waist.

22 Apr 2010

IL-10 Gene Therapy helps repair damaged lungs found unfit for transplant

Promising research brings hope for the almost two thousand lung transplant candidates who currently make up The United Network for Organ Sharing's (UNOS) wait list. A new technique that uses gene therapy to help repair damaged lungs previously found unfit for transplant shows promise for addressing the critical shortage of healthy donor organs.

22 Apr 2010

ISHLT announces new guidelines for heart transplant recipients

The International Society for Heart and Lung Transplantation (ISHLT) today announces new guidelines to standardize care for heart transplant patients worldwide. The guidelines demonstrate a united effort to decrease complications, improve outcomes and increase patient survival rates among heart transplant recipients. The guidelines will be presented during today's symposium The ISHLT Guidelines for Heart Transplant Recipients: Towards an International Consensus at the ISHLT 30th Annual Meeting and Scientific Sessions at the Hilton Chicago.

22 Apr 2010

California's first Community Safety Saturday to be hosted in Carmel Plaza

The Protector Network and Capital Insurance Group Insurance Center's Central Valley Insurance Agency together with the California Highway Patrol and Visalia Police Department, host California's first Community Safety Saturday. This family friendly event will take place on Saturday, April 24, in the Carmel Plaza.

22 Apr 2010

AstraZeneca HealthCare Foundation's cardiovascular health program receives $25M charitable contribution

The AstraZeneca HealthCare Foundation announced today it received a $25 million charitable contribution from AstraZeneca for Connections for Cardiovascular Health(SM), its newest program with the mission of improving cardiovascular health in the United States.

22 Apr 2010

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Interest in cancer prevention is increasing as scientists continue to learn new information and confirm what was already suspected.

22 Apr 2010

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).

22 Apr 2010

Report highlights 11 key categories of diseases, health consequences that occur due to climate change

A report released today by a federal working group highlights 11 key categories of diseases and other health consequences that are occurring or will occur due to climate change. The report, A Human Health Perspective on Climate Change, provides a starting point for coordination of federal research to better understand climate's impact on human health.

22 Apr 2010

Medical technology innovation strives for personal focus, cost-efficiency

Medtronic CEO Bill Hawkins says the products made by his company, like pacemakers, insulin pumps and neurostimulators are the "ultimate personal technologies," according to CNNMoney. He said a shift in his industry is moving towards health information technology that people will depend on and use with their cell phones and laptops.

22 Apr 2010

Heart Disease News and Research

Latest Heart Disease News and Research

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

SVS publishes first supplement on diversity articles to Journal of Vascular Surgery

Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor

Tryton Medical widens European availability of Side Branch Stent System

Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress

Genetic tests that may replace biopsies

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Boston Scientific introduces new Kinetix Guidewire for use in PCI procedures

Acacia Research reports record first-quarter license fee revenues of $39.77M

AB SCIEX to collaborate in disease studies with Samuel Lunenfeld Research Institute of Mount Sinai Hospital

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

New campaign highlights dangers of carrying excess weight around waist

IL-10 Gene Therapy helps repair damaged lungs found unfit for transplant

ISHLT announces new guidelines for heart transplant recipients

California's first Community Safety Saturday to be hosted in Carmel Plaza

AstraZeneca HealthCare Foundation's cardiovascular health program receives $25M charitable contribution

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Report highlights 11 key categories of diseases, health consequences that occur due to climate change

Medical technology innovation strives for personal focus, cost-efficiency

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Heart Disease News and Research

Latest Heart Disease News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in